IPBS Advances the Fight Against Antimicrobial Resistance

IPBS Research: A Multidisciplinary Force Against Resistance

At IPBS, several teams are pushing the frontiers of AMR research through complementary expertise.
The institute’s long-standing strength in tuberculosis research is embodied in the Guilhot team, which dissects the molecular strategies enabling Mycobacterium tuberculosis to survive stress and persist in the host. This work closely intersects with that of the Marrakchi group, which explores the architecture and biogenesis of the mycobacterial cell envelope, an essential barrier responsible for much of the bacterium’s antibiotic tolerance and a source of promising therapeutic targets.
Understanding how the immune system detects and eliminates pathogens is central to the research led by the Meunier lab, whose work sheds light on how innate immune mechanisms influence bacterial survival and resistance. Structural insights provided by the Mourey, Saurel/Atkinson and Schiltz laboratories further enrich these efforts, revealing the architecture of essential bacterial protein assemblies that can be exploited for drug discovery.
Host-pathogen interactions, a key driver of infection outcome and resistance, are deciphered by the Neyrolles team, while the Nigou laboratory focuses on the remarkable ability of mycobacterial lipids to modulate immune responses and shape disease progression. Completing this continuum, the newly created Ung group investigates membrane proteins that underpin bacterial physiology, from nutrient acquisition to stress responses, many of which play critical roles in resistance mechanisms.
Together, these teams form a vibrant, interdisciplinary community positioning IPBS as a leading center of innovation in the fight against antibiotic-resistant bacteria.